AMRN Stock Recent News
AMRN LATEST HEADLINES
GTX, LPG and AMRN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 27, 2025.
AMRN jumps 27% after inking an exclusive EU licensing deal with Recordati to expand Vazkepa's reach and cut costs.
Amarin (AMRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA ® IN EUROPE
From a technical perspective, Amarin Corporation PLC (AMRN) is looking like an interesting pick, as it just reached a key level of support. AMRN's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
Here is how Amarin (AMRN) and GSK (GSK) have performed compared to their sector so far this year.
Amarin (AMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AMRN, FIX and PATH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 10, 2025.
FIX, GHLD, AMRN, VCISY and NWFL have been added to the Zacks Rank #1 (Strong Buy) List on June 10, 2025.
AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis.